Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03346668 · ClinicalTrials.gov registry record · Early Phase 1
Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia
A Early Phase 1 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 5
- Enrollment target
NCT03346668: Completed Early Phase 1 study, sponsored by University of Minnesota.
NCT03346668 is a Early Phase 1 study that has completed, run by University of Minnesota. The registered enrollment target is 5 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03346668, a Early Phase 1 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study will serve as a pilot study to determine the efficacy and safety of topical gabapentin in the treatment of symptomatic scarring alopecia.
Primary Outcome
Complete a QOL (Quality of Life) survey Scale= (Not relevant to Extremely Relevant)
Interventions
- DRUG Topical gabapentin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2016-01-28 |
| Est. Completion | 2021-10-11 |
| Phase | Early Phase 1 |
What the finished NCT03346668 record still lists
NCT03346668 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 1 intervention - of which Topical gabapentin is the first listed.
NCT03346668 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03346668 about?
NCT03346668 is a clinical study titled "Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia". This study will serve as a pilot study to determine the efficacy and safety of topical gabapentin in the treatment of symptomatic scarring alopecia.
What is the current status of trial NCT03346668?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 5 participants. The study started on 2016-01-28. Estimated completion is 2021-10-11.
What interventions are being tested in trial NCT03346668?
The interventions under investigation include: Topical gabapentin (DRUG).
Who is sponsoring clinical trial NCT03346668?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03346668's enrollment target sits among peer trials
5 1888th of 2000 higher than 80 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI